Veradigm (MDRX) announced that its board of directors completed its previously announced review of strategic alternatives. “Throughout the ...

Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the “ ...

The health tech company formerly known as Allscripts, still reeling from failing to fix its financial reports, will have to ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

For its internal medicines initiatives, the business has started looking for strategic substitutes including possible asset sales or licencing deals. Unless a clear agreement is achieved or legal ...

The Special Committee of the board of 23andMe Holding Co. announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a poss ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

However, the Company did not receive any final proposals. "The Board undertook the review of strategic alternatives with the primary objective of maximizing stockholder value," stated Greg ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.